INS and familial primary hypomagnesemia: Dolutegravir interferes with magnesium at the cellular level, causing hypomagnesemia, which results in reduced insulin secretion from the pancreas and resistance at the receptors (GLUT 4) on the target tissues; hence, hyperglycemia [16].